Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells 1,127 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Brian Savage sold 1,127 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $35,692.09. Following the completion of the transaction, the insider directly owned 10,914 shares in the company, valued at $345,646.38. This represents a 9.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Teva Pharmaceutical Industries Trading Up 1.3%

Shares of TEVA stock traded up $0.39 during trading hours on Monday, reaching $31.44. 11,093,304 shares of the stock traded hands, compared to its average volume of 9,695,220. The business has a fifty day moving average price of $33.01 and a 200 day moving average price of $26.32. The firm has a market capitalization of $36.15 billion, a PE ratio of 26.20, a PEG ratio of 10.39 and a beta of 0.72. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same period in the prior year, the firm earned $0.71 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Recent fundamentals and guidance support the stock’s strength — Teva beat Q4 EPS and revenue in its Jan 28 report, reported improving margins and set FY2026 EPS guidance of 2.57–2.77, which gives investors clearer earnings visibility and helps justify the rally.
• Neutral Sentiment: Management presented at the Leerink Global Healthcare Conference; the transcript provides investor-facing commentary on strategy, pipeline and commercial performance but contains no market-moving surprise in the headlines. Teva Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Heavy insider selling reported on March 5 by multiple senior executives (CEO and several EVPs). Notable filings show CEO Richard D. Francis sold 20,025 shares (~$31.67 avg), and other insiders (Placid Jover, Richard Daniell, Eric A. Hughes, Christine Fox, Brian Savage) also trimmed positions — in some cases materially (Placid Jover’s position fell ~67.6%). Large, clustered insider sales can weigh on sentiment even if they are for diversification or tax reasons. SEC filing for the CEO sale is available here: CEO Filing. The sales were also summarized by the press: Insider Selling: CEO Sells

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently modified their holdings of TEVA. AQR Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after buying an additional 4,732 shares during the period. Focus Partners Wealth raised its position in Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after buying an additional 1,739 shares during the last quarter. Bank of Montreal Can grew its stake in shares of Teva Pharmaceutical Industries by 15.9% during the 2nd quarter. Bank of Montreal Can now owns 475,937 shares of the company’s stock worth $7,977,000 after acquiring an additional 65,191 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Teva Pharmaceutical Industries by 4.5% in the second quarter. Bank of New York Mellon Corp now owns 1,682,837 shares of the company’s stock worth $28,204,000 after purchasing an additional 73,141 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. grew its position in Teva Pharmaceutical Industries by 5.3% in the second quarter. Resona Asset Management Co. Ltd. now owns 360,316 shares of the company’s stock valued at $6,039,000 after purchasing an additional 18,093 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TEVA. The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Jefferies Financial Group boosted their price objective on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Finally, Piper Sandler reissued an “overweight” rating and set a $41.00 price objective (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $37.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.